SCHEMBL4598725

SCHEMBL4598725

OCC1=NOCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18587487 0.85
SCHEMBL16962034 0.80
SCHEMBL17307519 0.80
SCHEMBL6186727 0.74
SCHEMBL17629784 0.74
SCHEMBL16634400 0.69
SCHEMBL3672880 0.69
SCHEMBL28304533 0.62
SCHEMBL17629781 0.62
SCHEMBL10343777 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1404661-B1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA SPA (IT) 2008-04-09 EP claimed
EP-1404661-A1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA S.p.A. (IT) 2004-04-07 EP claimed
WO-2002090341-A1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA S.P.A. (IT) 2002-11-14 WO claimed
WO-2026107422-A1 6-(PYRIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE BRISTOL-MYERS SQUIBB COMPANY (US) 2026-05-21 WO disclosed
CN-106687458-B Substituted oxopyridine derivatives 拜耳制药股份公司 2020-10-27 CN disclosed
EP-3197872-B1 (2H)-2-OXOPYRIDINES AS FAKTOR XIA-INHIBITORS FOR TREATING THROMBOTIC DISEASES Bayer Pharma AG (DE) 2019-01-30 EP disclosed
US-10167280-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-01 US disclosed
EP-3197873-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2018-10-24 EP disclosed
US-20170298052-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-19 US disclosed
US-20170298052-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-19 US disclosed
US-20170298052-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-19 US disclosed
WO-2016046166-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-03-31 WO disclosed
WO-2016046164-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-03-31 WO disclosed
EP-1404661-B1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA SPA (IT) 2008-04-09 EP disclosed
EP-1404661-B1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA SPA (IT) 2008-04-09 EP disclosed
CN-1742015-A Oxazolidinone and / or isoxazoline derivatives as antibacterial agents ASTRAZENECA AB (SE) 2006-03-01 CN disclosed
EP-1404661-A1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA S.p.A. (IT) 2004-04-07 EP disclosed
EP-1404661-A1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA S.p.A. (IT) 2004-04-07 EP disclosed
WO-2002090341-A1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA S.P.A. (IT) 2002-11-14 WO disclosed
WO-2002090341-A1 PROCESS FOR THE PRODUCTION OF 5-BENZYL-3-FURFURYL ALCOHOL ENDURA S.P.A. (IT) 2002-11-14 WO disclosed